ArticleJournal of molecular histology2026
Modified Shenqi compound alleviated constipation and inflammation in diabetic mice by regulating the miR-23a-3p/Nrf2 axis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Constipation is a prevalent gastrointestinal complication in patients with diabetes mellitus (DM), characterized by infrequent bowel movements and difficulty in defecation. Modified Shenqi Compound (MSQC), a traditional Chinese medicine (TCM) formulation, has demonstrated therapeutic efficacy against DM; however, its mechanisms in alleviating diabetic constipation remain unclear. This study investigates the effects and underlying mechanisms of MSQC in a mouse model of diabetic constipation. Diabetic mice with constipation were treated with MSQC, and various parameters including constipation symptoms, intestinal mucosal damage, inflammatory response, gut microbiota composition, and oxidative stress were evaluated. Additionally, miR-23a-3p antagomir was used to investigate the role of the miR-23a-3p/Nrf2 axis in mediating the effects of MSQC. The results showed that MSQC administration significantly ameliorated constipation symptoms, attenuated intestinal mucosal damage, and reduced inflammatory responses. Moreover, MSQC modulated the gut microbiota profile, notably decreasing the abundance of Cryptobacteroides while increasing that of Faecalibaculum, Vagococcus_B. In addition, MSQC inhibited intestinal oxidative stress via upregulating miR-23a-3p, which in turn promoted the expression of its downstream target, Nrf2. Crucially, the co-administration of a miR-23a-3p antagomir reversed the therapeutic benefits of MSQC, counteracting its improvements on constipation symptoms, intestinal mucosal injury, and inflammation. In conclusion, MSQC effectively alleviates diabetic constipation through a multi-targeted mechanism involving the activation of the miR-23a-3p/Nrf2 antioxidant pathway, reinforcement of the intestinal barrier, suppression of inflammation, and restoration of gut microbial homeostasis. Our findings provide a mechanistic basis for the clinical application of MSQC in treating diabetic constipation.
Indexed as
Identifiers
41709028What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.